Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer
JCO Oncology Practice · 2023
DOI: 10.1200/op.22.00787 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2023. Verfasst von Avani M Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology at H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are highly effective for treatment of EGFR- or ALK-mutated lung cancer. Nevertheless, they are associated with several unique toxicities. Although the available US Food and Drug Administration (FDA)–approved drug label can provide guidance for safety monitoring, its integration into clinical practice has not been previously described. We studied the conduct of safety monitoring activity (SMA) at a large academic institution. On the basis of FDA-approved drug labels, two drug-specific SMAs were identified for osimertinib, crizotinib, alectinib, or lorlatinib. Electronic medical records of patients initiated on these drugs from 2017 to 2021 were retrospectively reviewed. Each course of treatment was evaluated for the occurrence of SMAs and the corresponding adverse events. Analyses included 130 treatment courses from 111 unique patients. For each SMA evaluated, the prevalence of SMA conduct ranged from 10.0% to 84.6%. The most frequently conducted SMA was ECG for lorlatinib therapy and the least was creatine phosphokinase analysis for alectinib. We observed none of the assessed SMAs being conducted in 41 treatment courses (31.5%). EGFR inhibitor predicted a higher likelihood of both SMAs being conducted than ALK inhibitors ( P = .02). Serious, grade 3 or 4 adverse events were observed in 21 treatment courses (16.2%), including one grade 4 transaminitis related to alectinib. On the basis of our experience, the conduct of SMA was more challenging to implement for ALK inhibitor than for EGFR inhibitor. Clinicians should be vigilant and review the FDA-approved drug label before prescribing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology at H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL.
- Morsani College of Medicine, University of South Florida, Tampa, FL.
- Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
- Department of Individualized Cancer Management, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
ORCID-Profile: Avani M Singh, Rafael Rubiera-Pebe, Yaser Ahmad, J Kevin Hicks, Tawee Tanvetyanon
Zitieren
APA
Singh, A. M., Rubiera-Pebe, R., Ahmad, Y., Shafique, M., Hicks, J. K., & Tanvetyanon, T. (2023). Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer. JCO Oncology Practice. https://doi.org/10.1200/op.22.00787
Vancouver
Singh AM, Rubiera-Pebe R, Ahmad Y, Shafique M, Hicks JK, Tanvetyanon T. Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer. JCO Oncology Practice. 2023. doi:10.1200/op.22.00787
BibTeX
@article{Singh2023,
author = {Singh, Avani M and Rubiera-Pebe, Rafael and Ahmad, Yaser and Shafique, Michael and Hicks, J Kevin and Tanvetyanon, Tawee},
title = {Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer},
journal = {JCO Oncology Practice},
year = {2023},
doi = {10.1200/op.22.00787}
}
EUVIMED